Control of endemic glycopeptide-resistant enterococci

Infect Control Hosp Epidemiol. 1996 May;17(5):286-92. doi: 10.1086/647297.

Abstract

Objective: To evaluate the epidemiology of, and control measures for, vancomycin-resistant Enterococcus (VRE) in a renal unit.

Design: A 3-month, prospective, prevalence culture survey of patients on a 24-bed renal unit.

Setting: A 975-bed community teaching hospital.

Patients: Patients admitted to the renal unit over a 3-month period. Patients identified with VRE were each matched with four patients without VRE isolated over the study period. INTERVENTIONS/CONTROL MEASURES: Resistant-organism barrier precautions. To eradicate carriage of VRE, two patients with VRE stool colonization were treated with 5 days of oral doxycycline (100 mg twice per day) and rifampin (300 mg/day).

Results: Seven patients with VRE (8 isolates) were identified. Five isolates were Enterococcus faecium (vancomycin MIC = 16 to 256 micrograms/mL), two were Enterococcus faecalis (MICs = 16 and 124 micrograms/mL), and one was Enterococcus gallinarum (MIC = 8.0 micrograms/mL). Eradication of carriage with VRE was accomplished in two patients treated with doxycycline and rifampin. In the final 30 days of the culture survey and at 9 months, there were no further patients with VRE identified.

Conclusions: Resistant-organism precautions and elimination of patient carriage may be useful measures for controlling the spread of low-prevalence endemic vancomycin-resistant Enterococcus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents*
  • Case-Control Studies
  • Cross Infection / prevention & control*
  • Drug Resistance, Microbial
  • Enterococcus faecalis*
  • Enterococcus faecium*
  • Female
  • Gram-Positive Bacterial Infections / prevention & control*
  • Humans
  • Infection Control / methods*
  • Kidney Diseases / complications
  • Male
  • Middle Aged
  • Prevalence
  • Prospective Studies
  • Vancomycin*

Substances

  • Anti-Bacterial Agents
  • Vancomycin